Vol 6, No 6 (2017)
Research paper
Published online: 2018-01-26

open access

Page views 1150
Article views/downloads 1019
Get Citation

Connect on Social Media

Connect on Social Media

Quality of care for type 2 diabetes mellitus in Tripoli Medical Center: a retrospective study of 628 patients

Hawa Juma El-Shareif1
Clin Diabetol 2017;6(6):204-210.

Abstract

Introduction. Diabetes mellitus (DM) is a major public health problem. Evidence has shown that aggressive control of hyperglycemia and associated risk factors reduces the risk of both macrovascular and micro­vascular complications. The aim of this study was to determine the proportion of diabetes patients reaching the targets recommended by The American Diabetes Association (ADA) standards for diabetes care.

Methods and materials. This is a retrospective study, conducted at the diabetes outpatient clinics at TMC. For 628 patients with diabetes with at least two clinic visits in the 24 months before August 2010, we as­sessed measurement and control of HbA1c, blood pressure, and lipid, the data were collected in a spe­cially designed data sheet, and analyzed using SPSS program.

Results. 628 patients were studied. The mean age was 49.6 ± 11.8 years; average duration of diabetes was 6.5 ± 5.0 years. The mean last HbA1c was 8.2 ± 2.4%. 75.1% attained a systolic blood pressure of < 140 and 75.7% attained a diastolic blood pressure of < 90 mm Hg. Only 30.8% had LDL cholesterol of < 100 mg/dL and 49.0% had a triglyceride level of < 150 mg/dL. The rate of annual foot examination, retinal examination screening, and urine microalbumin screening were low.

Conclusions. This study demonstrates a low rate of diabetes care targets achievement among patients with type 2 diabetes treated at TMC. (Clin Diabetol

2017; 6, 6: 204–210)

Article available in PDF format

View PDF Download PDF file

References

  1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2): 137–149.
  2. International diabetes federation (IDF) (2013) IDF Diabetes atlas. edn.6, International diabetes federation, Brussels, Belgium, Europe. Brussels, 2013.
  3. Kadiki OA, Roaeid RB. Prevalence of diabetes mellitus and impaired glucose tolerance in Benghazi Libya. Diabetes Metab. 2001; 27(6): 647–654.
  4. World Health Organization (2012) STEPwise surveillance of noncommunicable disease risk factors in the Eastern Mediterranean region. http://bit.ly/126n6Z1 (accessed 7.6.2013).
  5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258): 405–412.
  6. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013; 93(1): 137–188.
  7. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999; 159(16): 1873–1880.
  8. da Rocha Fernandes J, Ogurtsova K, Linnenkamp U, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016; 117: 48–54.
  9. Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015; 33(8): 811–831.
  10. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36(4): 1033–1046.
  11. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009; 120(3): 212–220.
  12. Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014; 7: 169–183.
  13. Nathan DM, Genuth S, Lachin J, et al. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977–986.
  14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837–853.
  15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317(7160): 703–713.
  16. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006; 332(7550): 1115–1124.
  17. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006; 333(7566): 475–480.
  18. Mayfield JA, Reiber GE, Sanders LJ, et al. Preventive Foot Care in People With Diabetes. Diabetes Care. 1998; 21(12): 2161–2177.
  19. Gross JL, Azevedo MJde, Silveiro SP, et al. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care. 2004; 28(1): 164–176.
  20. Bragge P, Gruen RL, Chau M, et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol. 2011; 129(4): 435–444.
  21. American Diabetes Association. American Diabetes Association Standards of Medical Care in Diabetes – 2017. Diabetes Care. 2017; 40(sup 1): S1–S138.
  22. Grant RW, Buse JB, Meigs JB, et al. University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005; 28(2): 337–442.
  23. Cooper JG, Claudi T, Jenum AK, et al. Quality of care for patients with type 2 diabetes in primary care in Norway is improving: results of cross-sectional surveys of 33 general practices in 1995 and 2005. Diabetes Care. 2009; 32(1): 81–83.
  24. Laxy M, Knoll G, Schunk M, et al. Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies. PLoS One. 2016; 11(10): e0164704.
  25. Alhyas L, McKay A, Balasanthiran A, et al. Quality of type 2 diabetes management in the states of the Co-operation Council for the Arab States of the Gulf: a systematic review. PLoS One. 2011; 6(8): e22186.
  26. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999; 22(11): 1785–1789.
  27. Larsen ML, Hørder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med. 1990; 323(15): 1021–1025.
  28. Yang S, Kong W, Hsue C, et al. Knowledge of A1c Predicts Diabetes Self-Management and A1c Level among Chinese Patients with Type 2 Diabetes. PLoS One. 2016; 11(3): e0150753.
  29. Badawi D, Saleh S, Natafgi N, et al. Quality of Type II Diabetes Care in Primary Health Care Centers in Kuwait: Employment of a Diabetes Quality Indicator Set (DQIS). PLoS One. 2015; 10(7): e0132883.
  30. Akel M, Hamadeh G. Quality of diabetes care in a university health center in Lebanon. Int J Qual Health Care. 1999; 11(6): 517–521.
  31. Kharal M, Al-Hajjaj A, Al-Ammri M, et al. Meeting the American Diabetic Association standards of diabetic care. Saudi J Kidney Dis Transpl. 2010; 21(4): 678–685.
  32. Al-Elq AH. Current practice in the management of patients with type 2 diabetes mellitus in Saudi Arabia. Saudi Med J. 2009; 30(12): 1551–1556.
  33. Alhyas L, Cai Y, Majeed A. Type 2 diabetes care for patients in a tertiary care setting in UAE: a retrospective cohort study. JRSM Short Rep. 2012; 3(10): 67.
  34. Al-Hussein F. Diabetes control in a primary care setting: a retrospective study of 651 patients. Ann Saudi Med. 2008; 28(4): 267–271.
  35. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291(3): 335–342.
  36. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21): 2005–2012.
  37. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008; 23(5): 588–594.
  38. TRIAD Study Group. Health Systems, Patients Factors, and Quality of Care for Diabetes: A synthesis of findings from the TRIAD Study. Diabetes Care. 2010; 33(4): 940–947.
  39. Beaton SJ, Nag SS, Gunter MJ, et al. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care. 2004; 27(3): 694–698.
  40. Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1575–1585.
  41. Al-Mandhari A, Al-Zakwani I, El-Shafie O, et al. Quality of Diabetes Care: A cross-sectional observational study in Oman. Sultan Qaboos Univ Med J. 2009; 9(1): 32–36.